14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic rejection Project. (Articolo in rivista)

Type
Label
  • 14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic rejection Project. (Articolo in rivista) (literal)
Anno
  • 2007-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1111/j.1399-0039.2006.00765.x (literal)
Alternative label
  • Ozawa M1; Terasaki PI2; Lee JH1; Castro R1; Alberu J3; C. Alonso4; Alvarez I5; Toledo R5; Alvez H6; Monterio M6; Teixeira J6; Campbell P7; Ciszcek M8; Charron D9; Gautreau C9; Christiansen F10; Conca R11; Gomez B12; Monteon F12; Grosse-Wilde H13; Heinemann F14; Humar I15; Kamoun M16; Kimball M17; Kobayashi T18; Kupatawintu P19; Leech S20; LeFor W21; Mehra N22; Panigrahi A22; Naumova E23; Norman D24; Piazza A25; Poli F26; Colombo B26; Roy R27; Schonemann C28; Sireci G29; Tanabe K30; Ishida H30; Van den Berg-Loonen E31; Zeevi A32. (2007)
    14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic rejection Project.
    in Tissue antigens
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Ozawa M1; Terasaki PI2; Lee JH1; Castro R1; Alberu J3; C. Alonso4; Alvarez I5; Toledo R5; Alvez H6; Monterio M6; Teixeira J6; Campbell P7; Ciszcek M8; Charron D9; Gautreau C9; Christiansen F10; Conca R11; Gomez B12; Monteon F12; Grosse-Wilde H13; Heinemann F14; Humar I15; Kamoun M16; Kimball M17; Kobayashi T18; Kupatawintu P19; Leech S20; LeFor W21; Mehra N22; Panigrahi A22; Naumova E23; Norman D24; Piazza A25; Poli F26; Colombo B26; Roy R27; Schonemann C28; Sireci G29; Tanabe K30; Ishida H30; Van den Berg-Loonen E31; Zeevi A32. (literal)
Pagina inizio
  • 174 (literal)
Pagina fine
  • 179 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 69s.1 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 6 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1One Lambda, Inc., Los Angeles, CA, USA; 2Terasaki Foundation Laboratory, Los Angeles, CA, USA; 3Dept. de Trasplantes, Instituto Nacional, Mexico City, Mexico; 4Hospital Juan Canalejo, La Coruna, Spain; 5Banco Nal De Organos, Uruguay; 6Centro de Histocompatibilidade do Norte, Porto, Portugal; 7University of Alberta, Edmonton, Alberta, Canada; 8Transplantation Institute, Warsaw, Poland; 9Laboratoire d'histocompatibilité et d'immunologie Hôpital Saint Louis, Paris, France; 10Royal Perth Hospital, Perth, Western Australia, Australia; 11Turin Transplant Immunology Service, Turin, Italy; 12Centro Medico de Occidente, Guadalajara, Mexico; 13University Hospital Medical School, Essen, Germany; 14Institute of Immunology, University Hospital, Essen, Germany; 15Zagreb, Zagreb, Croatia; 16University of Pennsylvania, Philadelphia, PA, USA; 17Medical College of Virginia, Richmond, VA, USA; 18Nagoya University School of Medicine, Nagoya, Japan; 19Bangkok, Thailand; 20Temple University, Philadelphia, PA, USA; 21LifeLink Foundation Inc., Tampa, FL, USA; 22All-India Institute of Medical Sciences, New Delhi, India; 23University Hospital Alexandrovska, Sofia, Bulgaria; 24Oregon Health Sciences University, Portland, OR, USA; 25Consiglio Nzionale, Rome, Italy; 26North Italy Reference Center, Milan, Italy; 27Laval University Hospital Center, Quebec, Canada; 28Charlite, Campus Virchow Kliuikuw, Berlin, Germany; 29Ospedale P. Giacone, Palermo, Italy; 30Tokyo Women's Medical University, Tokyo, Japan; 31University Hospital Maastricht, Maastricht, the Netherlands; 32University of Pittsburgh Medical Center, Pittsburgh, PA, USA (literal)
Titolo
  • 14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic rejection Project. (literal)
Abstract
  • An international collaborative study of 45 transplant centers was undertaken at the 14th International HLA (human leukocyte antigen) and Immunogenetics Workshop to see if HLA antibodies detected posttransplant are predictive of chronic graft failure. With the newly developed assay, MICA (major histocompatibility complex class I-related chain A) antibodies were also measured and their effect analyzed. Total of 5219 sera from patients who were more than 6 months posttransplant with functioning graft were tested for HLA antibodies by enzyme-linked immunosorbent assay, flow cytometry, or Luminex. HLA antibodies were found in 27.2% of kidney patients, 23.6% in the liver, 52.7% in the heart, and 21.7% in the lung. The method of antibody testing did not have a marked influence on the frequency of antibodies detected. MICA antibodies were detected in 15% of kidneypatients, 30% of heart patients, and 31% of liver patients. Among 948 kidney patients who had HLA antibodies, 7.3% had rejected their graft within 1 year of testing, compared with 1.7% in 2615 patients without HLA antibodies (P= 0.8 × 10-17). Death occurred in 1.4% of total kidney patients and did not correlate to the presence of antibodies. We conclude that patients with posttransplant HLA antibodies indeed have a higher rate of chronic graft failure and that posttransplant antibodies are predictive of chronic rejection. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Insieme di parole chiave di
data.CNR.it